NRx Pharmaceuticals (NASDAQ:NRXP) Stock Dropped to Strong Sell by Wall Street Zen

NRx Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded NRx Pharmaceuticals from “sell” to “strong sell,” though broader analyst sentiment remains more favorable: MarketBeat reports a “Moderate Buy” consensus and a $35 average price target.
  • NRx reported a quarterly loss of $0.05 per share, beating the $0.21 loss analysts expected, while revenue of $1.16 million came in below the $1.28 million estimate.
  • The stock opened at $2.15, below its 50-day and 200-day moving averages; it has traded between $1.62 and $5.05 over the past 52 weeks.
  • Five stocks to consider instead of NRx Pharmaceuticals.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.

NRXP has been the topic of several other research reports. BTIG Research boosted their price objective on NRx Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Wednesday, November 11th. Zacks Research raised NRx Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Monday, November 16th. HC Wainwright reissued a "buy" rating on shares of NRx Pharmaceuticals in a research note on Tuesday, August 25th. UBS Group restated a "buy" rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 26th. Finally, Wolfe Research initiated coverage on NRx Pharmaceuticals in a report on Thursday, October 15th. They set an "outperform" rating on the stock. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $35.00.

Read Our Latest Research Report on NRXP

NRx Pharmaceuticals Stock Performance

NASDAQ:NRXP opened at $2.15 on Friday. The firm's fifty day moving average is $2.72 and its 200-day moving average is $2.97. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $5.05. The firm has a market cap of $93.85 million, a P/E ratio of -6.32 and a beta of 2.11.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.16. The company had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.28 million. As a group, sell-side analysts anticipate that NRx Pharmaceuticals will post -1.14 earnings per share for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of NRXP. B Group Inc. increased its stake in NRx Pharmaceuticals by 4.5% during the 3rd quarter. B Group Inc. now owns 4,277,200 shares of the company's stock valued at $12,489,000 after purchasing an additional 185,433 shares in the last quarter. Marshall Wace LLP lifted its stake in NRx Pharmaceuticals by 411.4% during the 3rd quarter. Marshall Wace LLP now owns 995,172 shares of the company's stock valued at $2,906,000 after acquiring an additional 800,592 shares during the period. Commonwealth Equity Services LLC boosted its holdings in NRx Pharmaceuticals by 30.0% in the third quarter. Commonwealth Equity Services LLC now owns 590,768 shares of the company's stock worth $1,725,000 after purchasing an additional 136,350 shares during the last quarter. SBI Securities Co. Ltd. grew its holdings in shares of NRx Pharmaceuticals by 292.1% in the third quarter. SBI Securities Co. Ltd. now owns 20,001 shares of the company's stock worth $58,000 after acquiring an additional 14,900 shares during the period. Finally, Prime Capital Investment Advisors LLC bought a new position in shares of NRx Pharmaceuticals in the 3rd quarter worth approximately $364,000. Hedge funds and other institutional investors own 4.27% of the company's stock.

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company's candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.

Further Reading

Analyst Recommendations for NRx Pharmaceuticals (NASDAQ:NRXP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in NRx Pharmaceuticals Right Now?

Before you consider NRx Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NRx Pharmaceuticals wasn't on the list.

While NRx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines